Arrowhead Pharmaceuticals, Inc. (ARWR)
78.89
-0.38
(-0.48%)
USD |
NASDAQ |
Jun 26, 16:00
79.50
+0.61
(+0.77%)
Pre-Market: 20:00
Arrowhead Pharmaceuticals Cash from Financing (TTM) : 736.96M for March 31, 2026
Cash from Financing (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2026 | 736.96M |
| December 31, 2025 | 33.62M |
| September 30, 2025 | 74.01M |
| June 30, 2025 | 459.43M |
| March 31, 2025 | 557.49M |
| December 31, 2024 | 895.89M |
| September 30, 2024 | 870.52M |
| June 30, 2024 | 481.58M |
| March 31, 2024 | 433.00M |
| December 31, 2023 | 2.744M |
| September 30, 2023 | 253.05M |
| June 30, 2023 | 253.76M |
| March 31, 2023 | 312.55M |
| December 31, 2022 | 313.88M |
| September 30, 2022 | 65.19M |
| June 30, 2022 | 65.15M |
| March 31, 2022 | 7.301M |
| December 31, 2021 | 8.088M |
| September 30, 2021 | 11.30M |
| June 30, 2021 | 11.49M |
| March 31, 2021 | 10.87M |
| December 31, 2020 | 9.572M |
| September 30, 2020 | 257.95M |
| June 30, 2020 | 258.78M |
| March 31, 2020 | 259.41M |
| Date | Value |
|---|---|
| December 31, 2019 | 260.75M |
| September 30, 2019 | 66.38M |
| June 30, 2019 | 66.12M |
| March 31, 2019 | 64.81M |
| December 31, 2018 | 119.04M |
| September 30, 2018 | 59.95M |
| June 30, 2018 | 58.26M |
| March 31, 2018 | 56.81M |
| December 31, 2017 | 0.046M |
| September 30, 2017 | 12.06M |
| June 30, 2017 | 65.82M |
| March 31, 2017 | 68.03M |
| December 31, 2016 | 67.66M |
| September 30, 2016 | 55.13M |
| June 30, 2016 | 1.625M |
| March 31, 2016 | -0.6335M |
| December 31, 2015 | -0.3844M |
| September 30, 2015 | 0.2905M |
| June 30, 2015 | 0.6894M |
| March 31, 2015 | 5.085M |
| December 31, 2014 | 122.71M |
| September 30, 2014 | 185.29M |
| June 30, 2014 | 186.76M |
| March 31, 2014 | 217.72M |
| December 31, 2013 | 103.78M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (TTM) Benchmarks
| Twist Bioscience Corp. | 11.84M |
| Revolution Medicines, Inc. | 859.39M |
| ImmunityBio, Inc. | 625.15M |
| Vera Therapeutics, Inc. | 311.31M |
| Erasca, Inc. | 245.73M |